Towards Healthcare

Rossari Biotech Q1 FY26 Profit Drops 4% YoY Despite 11% Revenue Growth

Rossari Biotech reported a 4% YoY decline in Q1 FY26 net profit to ₹34 crore, while revenue rose 11% to ₹543.72 crore. Growth in HPPC and AHN segments supported the performance despite rising costs and weaker exports.

Author: Towards Healthcare Published Date: 23 July 2025
Share : linkedin twitter facebook

Rossari Biotech’s Q1 PAT Slides by 4% YoY to RS 34cr

Rossari Biotech financial report Q1 FY26 showing 4% profit drop with 11% revenue growth

About Rossari Biotech

Rossari Biotech is a specialty chemical manufacturer based in Mumbai, India, that provides intelligent and sustainable solutions for industrial consumers. Rossario Biotech operates manufacturing facilities, which are strategically located at Silvassa and Dahej. The company is an expert in offering home, personal care, & performance chemicals, animal health & nutrition, and textile specialty chemicals.

Q1 FY25-26 Result Analysis

  • Rossari’s net profit started at RS 34.90 crore in Q1 FY25 and dropped by 3.72% to Rs 33.60 crore in Q1 FY26.
  • Operational Revenue started at 489.65 crore, reflecting a quarter-on-quarter increase of 11.04% to RS 543.72 crore in Q1 FY 26.
  • Profit before tax stood at 46.10 crore by 30 June 2025, a decrease of 1.89% from Rs 46.99 crore in Q1 FY25.
  • Total expenses increased by 12. 50% to Rs 499.88 crore in Q1.
  • The material consumed cost stood at Rs 334.40 crore, about 17. 73% YoY.
  • Employee benefit cost stood at Rs 37.46 crore, about 31.07%.
  • Finance expenses stood at Rs 5.72 crore, about 55.43% YoY during the quarter.

Joint Statement on Companies' Performance

Edwar Meneses, promoter & executive chairman, and Sunil Chari, promoter & managing director, stated that, “despite all challenges and evolving environments. The company has offered steady performance in Q1 FY26. The HPPC and AHN segments’ growth is highlighted in this performance. Even though the export business has decreased from last year's quarter, the healthy growth is remaining, with companies' constant effective initiatives and focused efforts in product mixing.”

Due to companies' commitment efforts in changing operating environments, the HPPC and AHN segments have gained growth of 16% and 12%, respectively. With commissioning performed and targeting investments for the coming quarter, the company is projected to increase manufacturing capabilities, supply chain agility improvements, and enhance efforts in high-growth sectors, including agrochemicals, personal care, pharmaceuticals, and oil & gas.

Latest Insights